• Explore /
  • Poster
  • / CORE1: Phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).

CORE1: Phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).

Abstract Poster

Authors

null

Roger Li

Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

Roger Li , Gary D. Steinberg , Edward M. Uchio , Donald L. Lamm , Paras Shah , Ashish M. Kamat , Trinity Bivalacqua , Vignesh T. Packiam , Michael Jon Chisamore , John McAdory , Paola Grandi , Nataliya Hnat , James Burke

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Other GU Kidney and Bladder Cancer

Clinical Trial Registration Number

NCT04387461

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 4597)

DOI

10.1200/JCO.2022.40.16_suppl.4597

Abstract #

4597

Poster Bd #

88

Abstract Disclosures

Similar Posters

First Author: Ashish M. Kamat

First Author: Roger Li

Poster

2024 ASCO Genitourinary Cancers Symposium

Adverse effects and discontinuation of pembrolizumab in BCG refractory non-muscle invasive bladder cancer.

Adverse effects and discontinuation of pembrolizumab in BCG refractory non-muscle invasive bladder cancer.

First Author: Borivoj Golijanin

First Author: Yoo Na Kim